© 2022 MJH Life Sciences and AJMC. All rights reserved.
© 2022 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
January 24th 2022, 3:50pm
Women in the study were 3 times more likely to be affected by rheumatoid arthritis (RA) and nearly 4 times more likely to develop hypothyroidism, compared with men.
January 14th 2022, 10:25pm
A study found that frailty reduced the likelihood of comprehensive disease control achievement by patients with rheumatoid arthritis (RA) being treated with a biologic agent.
January 12th 2022, 10:35pm
Neither adalimumab nor secukinumab substantially affected a patient’s immune response to the Pfizer COVID-19 vaccine.
January 7th 2022, 6:00pm
The safety profiles of COVID-19 vaccines in patients with inflammatory rheumatic and musculoskeletal disease (RMD) was comparable with patients with non-inflammatory RMD and the general population, according to a new study.
January 6th 2022, 6:45pm
Investigation into myeloid-related protein 8/14 (MRP8/14) serves as an important next step of translational research to discovering a diagnostic biomarker for systemic juvenile idiopathic arthritis.
December 26th 2021, 1:00pm
Readers were most interested in articles about cost of therapy, drug efficacy, and a unique case related to COVID-19.
December 24th 2021, 9:45pm
A study of the adult Korean population found high salt intake was associated with an increase in major adverse cardiovascular events (MACE) in patients with rheumatoid arthritis (RA).
December 23rd 2021, 3:00pm
Secukinumab is approved for use among patients with enthesitis-related arthritis (ERA) aged 4 years and up, and those with psoriatic arthritis (PsA) who are at least 2 years old.
December 17th 2021, 6:27pm
Stacy Courtnay is the community network chair for the Arthritis Foundation in Atlanta highlights a report that discusses how understanding patient experiences in RA can shift questions researchers ask.
December 15th 2021, 1:16pm
With a low number of approved medications for pediatric plaque psoriasis, secukinumab is a valuable new addition to the limited treatment options available.